SUPN - Supernus Pharmaceuticals GAAP EPS of $0.43 misses by $0.02 revenue of $152.51M beats by $2.04M

Supernus Pharmaceuticals press release (NASDAQ:SUPN): Q1 GAAP EPS of $0.43 misses by $0.02. Revenue of $152.51M (+16.5% Y/Y) beats by $2.04M. Non-GAAP operating income of $28.0 million. U.S. Food and Drug Administration approved Qelbree® for the treatment of ADHD in adults. Qelbree continued its growth trajectory, with 47,324 prescriptions in first quarter 2022, a 38% increase compared to fourth quarter 2021. GOCOVRI® prescriptions in first quarter 2022 reached 10,736, a 23% growth compared to first quarter 2021.

For further details see:

Supernus Pharmaceuticals GAAP EPS of $0.43 misses by $0.02, revenue of $152.51M beats by $2.04M